

Attorney Docket No. 6567.200-US
Sorensen et al.
Serial No. 10/735,963
Filed December 15, 2003

RECEIVED
CENTRAL FAX CENTER

SEP 13 2007

RESPONSE

The examiner states in the Office Action Summary that claims numbered 1-4, 6-8, 10-12 and 18-67 are pending in the application, claims numbered 1-4, 6-8, 10-12 and 18-52 are allowed, and claims 53-64 are withdrawn.

Claims numbered 3, 4, 6, and 51 are amended herein; claims numbered 53-67 are cancelled herein. No new matter would be added by these amendments.

Applicant has amended claims numbered 3, 4 and 6 to remove inadvertent typographical errors. Support for this amendment can be found in the claims as originally filed. Applicant has amended claim number 51 to clarify the claim language. Applicant has cancelled the previously withdrawn claims numbered 53-67, without prejudice, and reserves the right to pursue cancelled claims in a continuing application.

Applicants believe the claims are in condition for allowance. The examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

Date: September 13, 2007



Rosemarie R. Wilk-Orescan
Registration Number 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

US PATENT & TRADEMARK OFFICE